Sean Colm Turner

This inventor holds 49 USPTO granted patents and 13 published patent applications, plus 14 CIPO patents and 23 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Abbott Gmbh & Co Kg, Abbvie Deutschland Gmbh and Co Kg, Abbvie Inc.. Active years: 2005-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sean Colm Turner. Retrieved from https://idiyas.com/inventor/sean-colm-turner

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 49 (Patent Applications = 13)

% Patents Active = 30.6

CIPO Patents = 14 (Patent Applications = 12)

EPO Patents = 23 (Patent Applications = 24)

Average Co-Inventor Count = 7.3

ph-index = 8

Forward Citations = 193(Granted Patents)

Location History:

Mannheim, GB (2010)
Evanston, IL (US) (2005 - 2012)
Wiesbaden, DE (2016 - 2017)
Mannheim, DE (2006 - 2018)
Ludwigshafen, DE (2012 - 2020)

Company Filing History:

Abbvie Deutschland Gmbh and Co Kg

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2005-2020

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Glycogen Synthase Kinase-3

Kinase Inhibitors

5-HT Receptors

Dopamine D3 Receptor

Phosphodiesterase Type 10A

Isoxazolopyridazinones

Pyrazolopyrimidines

Phenalkylamine Derivatives

Quinoline Compounds

Fused Heterocyclic Compounds

Thienopyridyl Compounds

49 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10556914 - Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use (2020-02-11),

2. 10556907 - Fused heterocyclic compounds as S1P modulators (2020-02-11),

3. 10155770 - Substituted pyrazolopyrimidines and method of use (2018-12-18),

4. 10100048 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors (2018-10-16),

5. 9879033 - Modulators of 5-HT receptors and methods of use thereof (2018-01-30),

6. 9856234 - Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors (2018-01-02),

7. 9828381 - Substituted pyrazolopyrimidines and method of use (2017-11-28),

8. 9790203 - Inhibitor compounds of phosphodiesterase type 10A (2017-10-17),

9. 9657034 - Substituted furo[3,2-c]pyridines, thieno[3,2-c]pyridines, thieno[2,3-d]pyridazines and pyrido[3,4-d]pyridazines as phosphodiesterase type 10A inhibitors (2017-05-23),

10. 9540370 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors (2017-01-10),

11. 9273068 - Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A (2016-03-01),

12. 9266855 - Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors (2016-02-23),

13. 9238619 - Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy (2016-01-19),

14. 9187483 - Modulators of 5-HT receptors and methods of use thereof (2015-11-17),

15. 9163007 - 5-substituted indazoles as kinase inhibitors (2015-10-20),

Title: Sean Colm Turner: Pioneering Innovations in Mannheim

Introduction: Sean Colm Turner, a visionary inventor based in Mannheim, Germany, has left an indelible mark on the world of technology through his relentless pursuit of innovation. With a total of 49 patents to his name, Turner continues to inspire the next generation of inventors and shape the future of technology.

Latest Patents: Among Turner's latest patents are groundbreaking inventions that have the potential to revolutionize the field of pharmaceuticals. One of his patents focuses on fused heterocyclic compounds as S1P modulators, which have shown promising results in the treatment, alleviation, or prevention of diseases mediated by an S1P receptor. Another patent highlights substituted isoxazolopyridazinones and isothiazolopyridazinones, which exhibit positive allosteric modulation of the GABA-B receptor, offering new possibilities for treating various conditions.

Career Highlights: Throughout his illustrious career, Sean Colm Turner has made significant contributions to the field of biopharmaceuticals through his innovative research and patented inventions. With a strong focus on drug development and therapeutic interventions, Turner has paved the way for novel treatment approaches that address unmet medical needs.

Collaborations: Turner's collaborative efforts have further enriched his inventive journey. Working alongside talented individuals such as Karla Drescher and Wilfried Martin Braje, Turner has harnessed the power of teamwork to bring his innovative concepts to fruition. Collaborations with companies like AbbVie Deutschland GmbH & Co. KG and Abbott GmbH & Co. KG have provided Turner with valuable resources and support to advance his inventions.

Conclusion: Sean Colm Turner's unwavering dedication to innovation and his trailblazing spirit serve as a beacon of inspiration for aspiring inventors worldwide. His contributions to the field of technology and pharmaceuticals underscore the transformative power of creativity and perseverance. As Turner continues to push the boundaries of innovation, his impact on shaping the future of technology remains profound and enduring.

Profile summary based on public USPTO records.